A Clinical Trial of Infliximab for Childhood Uveitis

Inclusion Criteria: * Ages 4 to 18 years old, * Non-infectious uveitis * Persistent uveitis uncontrolled by topical medications, or unacceptable side effects of topical medications. * Failure of at least six weeks of treatment with a non-biological disease modifying agent such as methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine. * Ability to provide informed consent (subject or parent/guardian) * Onset of uveitis \< 16 years of age. * Topical ophthalmologic treatments allowed. * Systemic corticosteroid use at entry may be allowed. * Participant must be able to cooperate for a non-sedated slit lamp exam and visual acuity examination. * Negative Purified Protein Derivative (PPD) placed and read within 1 month of initiation of infliximab * The screening laboratory test results must meet the following criteria: WBC (white blood cell count): within normal range for institution ANC (absolute neutrophil count): within normal range for institution Hemoglobin: greater than 10 grams/deciliter Platelets: within normal range for institution Serum Creatinine: within normal range for age AST - aspartate aminotransferase - within normal range for institution ALT - alanine aminotransferase- within normal range for institution Exclusion Criteria: * Previous use of biologic medications for uveitis. * Intraocular steroid injection or ophthalmologic surgery within the preceding 3 months. * Uveitis due to trauma or intraocular surgery * A history of a known allergy to murine products. * Documentation of seropositivity for human immunodeficiency virus (HIV). * Documentation of a positive test for hepatitis B surface antigen or hepatitis C * A known history of a serious infection (e.g., hepatitis, pneumonia, or pyelonephritis) in the previous 3 months. * An opportunistic infection (e.g., herpes zoster \[shingles\], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening. * A concomitant diagnosis or history of congestive heart failure. * A history of lymphoproliferative disease. * Any known malignancy or a history of malignancy. * Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease. * Use of any investigational drug within 30 days prior to screening or within five half-lives of the first dose of the investigational agent, whichever is longer. * Presence of a transplanted solid organ.